Company or ticker...

Beam Therapeutics

Beam develops base-editing therapies that can rewrite single DNA letters.

Ticker

M. Cap

PS

PE

YTD

10MA

20MA

50MA

200MA

BEAM

3.6B

21.8

n/a

25.31%

Key Facts

M. Cap

PS

PE

YTD

3.6B

21.8

n/a

25.31%

10MA

20MA

50MA

200MA

$BEAM